lobbying_activities: 2769704

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2769704	c63b8fa8-5ae8-428e-afd2-20e3aa7917d5	Q1	JAMES EDWARDS	401027897	CONSERVATIVES FOR PROPERTY RIGHTS	2022	first_quarter	MMM	Price controls proposals regarding pharmaceuticals or other medical goods or services, including direct government price-setting of drugs in Medicare, Medicaid, and/or private insurance plans H.R. 3 (Lower Drug Costs Now Act) Interim Final Rule implementing a Most Favored Nation (MFN) Model for importing foreign price controls for certain Medicare Part B drugs (CMS-5528-IFC) S.Con.Res. 14 (FY22 Budget Resolution) price control provisions to repeal noninterference clause in Medicare Parts C & D H.R. 2884 (Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act) H.R. 5237 (Reduced Costs and Continued Cures Act) H.R. 5376 and subsequent versions of FY 2022 Budget Reconciliation price control provisions from H.R. 3, including repeal of noninterference clause in Medicare Parts C & D, and provisions expanding government-run health care, restrictions on private, Medicare, and Medicaid rates, coverage, and reimbursement, Medicare program changes reducing beneficiary choice, plan design, and competition	HOUSE OF REPRESENTATIVES,SENATE	30000		0	0	2022-04-04T11:17:59-04:00